Chandler H. Park, MD | Authors


Park Discusses Targeted Therapy Trials in Intermediate- and High-Risk ccRCC

February 21, 2021

In a 7 to 1 vote, oncologists favored the use of axitinib in combination with pembrolizumab or avelumab over cabozantinib monotherapy for the treatment of intermediate and high-risk clear cell renal cell carcinoma. Chandler H. Park, MD, reviewed that clinical trial research that supports the axitinib combinations, as well as other targeted therapy options.